News 2013

Starting with a severely affected family, a research team led by Jeanette Erdmann, Christian Hengstenberg and Heribert Schunkert (Institut für Integrative und Experimentelle Genomik, University of Lübeck and Deutsches Herzzentrum München) identified a novel mechanism leading to...

An international team of scientists, among them scientists of the DZHK, discovered an important fundamental process in hearts from patients with advanced heart failure, allowing a better understanding of the origin of this disease. Previously, it was already noted that...

Start for Europe-wide and only fully publicly funded ICD- patient study EU CERT ICD with significant participation of DZHK partners: UMG heart center coordinates.

Up to this point, implantable cardioverter defibrillators (ICD) were considered a life insurance against sudden...

The company Boehringer Ingelheim is continuing its support for the Gutenberg Health Study (GHS) with a sum of three million Euros by the end of 2017. Thereby, the GHS which started in 2007 is backed up until the end of that year. The aim is to build a biobank based on the data...

Göttingen pharmacologists led by DZHK - scientist Prof. Dr. Ali El - Armouche explore new therapy for heart failure: they activate the heart’s self-protection systems through targeted stimulation.

Currently, there is no therapy for myocardial weakness that can stop the...

Scientific know-how and skills of external partners are sought after in the German Centre for Cardiovascular Research (DZHK). Therefore it is now possible for scientists and institutions which are non-members of the DZHK to offer their specific methods or laboratory procedures...

In the future, The German Centre for Cardiovascular Research (DZHK) will cooperate with the Competence Network for Congenital Heart Defects and the Competence Network on Atrial Fibrillation. Parts of the scientific infrastructures of the two competence networks are planned to be...

Atherosclerosis, an inflammatory reaction, is at the root of the most common forms of cardiovascular disease. DZHK researchers from Munich have now identified a microRNA that plays a prominent role in the process, and offers a promising target for new therapies. ...